Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2
© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology..
In recent years, rapid advancement in gene/protein analysis technology has resulted in target molecule identification that may be useful in cancer treatment. Therefore, "Clinical Practice Guidelines for Molecular Tumor Marker, Second Edition" was published in Japan in September 2021. These guidelines were established to align the clinical usefulness of external diagnostic products with the evaluation criteria of the Pharmaceuticals and Medical Devices Agency. The guidelines were scoped for each tumor, and a clinical questionnaire was developed based on a serious clinical problem. This guideline was based on a careful review of the evidence obtained through a literature search, and recommendations were identified following the recommended grades of the Medical Information Network Distribution Services (Minds). Therefore, this guideline can be a tool for cancer treatment in clinical practice. We have already reported the review portion of "Clinical Practice Guidelines for Molecular Tumor Marker, Second Edition" as Part 1. Here, we present the English version of each part of the Clinical Practice Guidelines for Molecular Tumor Marker, Second Edition.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
International journal of clinical oncology - 29(2024), 5 vom: 16. Apr., Seite 512-534 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kikuchi, Yoshinori [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers, Tumor |
|---|
| Anmerkungen: |
Date Completed 25.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10147-024-02497-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369831497 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369831497 | ||
| 003 | DE-627 | ||
| 005 | 20240425233203.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240318s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10147-024-02497-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM369831497 | ||
| 035 | |a (NLM)38493447 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kikuchi, Yoshinori |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology. | ||
| 520 | |a In recent years, rapid advancement in gene/protein analysis technology has resulted in target molecule identification that may be useful in cancer treatment. Therefore, "Clinical Practice Guidelines for Molecular Tumor Marker, Second Edition" was published in Japan in September 2021. These guidelines were established to align the clinical usefulness of external diagnostic products with the evaluation criteria of the Pharmaceuticals and Medical Devices Agency. The guidelines were scoped for each tumor, and a clinical questionnaire was developed based on a serious clinical problem. This guideline was based on a careful review of the evidence obtained through a literature search, and recommendations were identified following the recommended grades of the Medical Information Network Distribution Services (Minds). Therefore, this guideline can be a tool for cancer treatment in clinical practice. We have already reported the review portion of "Clinical Practice Guidelines for Molecular Tumor Marker, Second Edition" as Part 1. Here, we present the English version of each part of the Clinical Practice Guidelines for Molecular Tumor Marker, Second Edition | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Driver genes | |
| 650 | 4 | |a Tumor markers | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 700 | 1 | |a Shimada, Hideaki |e verfasserin |4 aut | |
| 700 | 1 | |a Yamasaki, Fumiyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Yamashita, Taku |e verfasserin |4 aut | |
| 700 | 1 | |a Araki, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Horimoto, Kohei |e verfasserin |4 aut | |
| 700 | 1 | |a Yajima, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yashiro, Masakazu |e verfasserin |4 aut | |
| 700 | 1 | |a Yokoi, Keigo |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Haruhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Ehira, Takuya |e verfasserin |4 aut | |
| 700 | 1 | |a Nakahara, Kazunari |e verfasserin |4 aut | |
| 700 | 1 | |a Yasuda, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Isobe, Kazutoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashida, Tetsu |e verfasserin |4 aut | |
| 700 | 1 | |a Hatakeyama, Shingo |e verfasserin |4 aut | |
| 700 | 1 | |a Akakura, Koichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Aoki, Daisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Nomura, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Tada, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshimatsu, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Miyachi, Hayato |e verfasserin |4 aut | |
| 700 | 1 | |a Takebayashi, Chiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Hanamura, Ichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Hiroyuki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of clinical oncology |d 1997 |g 29(2024), 5 vom: 16. Apr., Seite 512-534 |w (DE-627)NLM095566163 |x 1437-7772 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:5 |g day:16 |g month:04 |g pages:512-534 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10147-024-02497-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 5 |b 16 |c 04 |h 512-534 | ||